Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,869,395
  • Shares Outstanding, K 74,389
  • Annual Sales, $ 851,100 K
  • Annual Income, $ 4,600 K
  • 60-Month Beta 0.96
  • Price/Sales 2.16
  • Price/Cash Flow 10.64
  • Price/Book 1.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.23
  • Number of Estimates 4
  • High Estimate 0.23
  • Low Estimate 0.22
  • Prior Year 0.30
  • Growth Rate Est. (year over year) -23.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.10 +24.38%
on 11/05/19
35.29 -29.16%
on 11/04/19
-5.57 (-18.22%)
since 10/18/19
3-Month
20.10 +24.38%
on 11/05/19
35.29 -29.16%
on 11/04/19
+0.51 (+2.08%)
since 08/20/19
52-Week
20.10 +24.38%
on 11/05/19
48.40 -48.35%
on 08/02/19
-6.70 (-21.14%)
since 11/20/18

Most Recent Stories

More News
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf...

MYGN : 25.00 (-0.52%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - MYGN

Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc. ("Myriad" or the "Company") (NASDAQ: MYGN) and certain of its officers. The class action, filed in United...

MYGN : 25.00 (-0.52%)
The American College of Rheumatology Adds the Vectra(R) Test to List of Recommended Disease Activity Measures for Rheumatoid Arthritis

Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced that the American College of Rheumatology (ACR) has included the Vectra test in its list...

MYGN : 25.00 (-0.52%)
ROSEN, A GLOBALLY RANKED LAW FIRM, Reminds Myriad Genetics, Inc. Investors of Important Deadline in Securities Class Action - MYGN

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Myriad Genetics, Inc. (NASDAQ: MYGN) from September 2, 2016 through August 13, 2019, inclusive (the "Class Period")...

MYGN : 25.00 (-0.52%)
CLASS ACTION UPDATE for COF, WTRH, MYGN and SDC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

COF : 96.51 (-0.58%)
WTRH : 0.35 (-5.59%)
MYGN : 25.00 (-0.52%)
SDC : 9.00 (+0.45%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - MYGN

Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc. ("Myriad" or the "Company") (NASDAQ: MYGN) and certain of its officers. The class action, filed in United...

MYGN : 25.00 (-0.52%)
9-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching

Hagens Berman urges Myriad Genetics, Inc. (NASDAQ: MYGN) investors who have suffered losses in excess of $50,000 to submit their losses now or contact the firm immediately to learn if they qualify to recover...

MYGN : 25.00 (-0.52%)
Myriad Genetics, Inc. (MYGN), Overstock.com, Inc. (OSTK) & Waitr Holdings Inc. (WTRH) - Bronstein, Gewirtz & Grossman, LLC Class Action Announcement

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...

MYGN : 25.00 (-0.52%)
OSTK : 7.92 (+0.51%)
WTRH : 0.35 (-5.59%)
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in MYGN, TME, and OSTK of Filing Deadlines

Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of MYGN, TME, and OSTK. If you wish to serve as lead plaintiff, you must move the court by the lead...

MYGN : 25.00 (-0.52%)
TME : 12.14 (+0.25%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tencent, Myriad Genetics, Overstock.com, and Waitr Holdings and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Tencent Music Entertainment Group...

TME : 12.14 (+0.25%)
MYGN : 25.00 (-0.52%)
OSTK : 7.92 (+0.51%)
WTRH : 0.35 (-5.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade MYGN with:

Business Summary

Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering...

See More

Key Turning Points

2nd Resistance Point 25.67
1st Resistance Point 25.34
Last Price 25.00
1st Support Level 24.66
2nd Support Level 24.31

See More

52-Week High 48.40
Fibonacci 61.8% 37.59
Fibonacci 50% 34.25
Fibonacci 38.2% 30.91
Last Price 25.00
52-Week Low 20.10

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar